Michael Hahn

Principal Scientist at Takeda Pharmaceutical Company

Lexington, Massachusetts, United States

About

Formulation scientist, biochemist, and team leader with consistent record of research excellence demonstrated by peer-reviewed publications and 9 years of industrial experience Specialties: Liquid and lyophilized formulation development of parenterals Protein biochemistry, Tech transfer, Regulatory filings, Team leadership

Experience

  • Principal Scientist at Takeda Pharmaceutical Company
    Jan 2019 - Present · 7 yrs 7 mos

  • Shire Pharmaceuticals ()
    • Principal Scientist
      Aug 2014 - Dec 2018 · 4 yrs 5 mos

      Technical leader for the pharmaceutical development of pipeline products (biologics) Develop formulation processes for drug substance and drug product throughout their product lifecycle using Quality by Design principles Subject matter expert for biologics drug product manufacture, stability and technology transfer Author regulatory submissions to support clinical development and licensure Lead Process Development Project Team and clinical state CMC Team

    • Senior scientist
      Apr 2010 - Jul 2014 · 4 yrs 4 mos

      Pharmaceutical development of protein products from nonclinical to clinical phase Pre-formulation and formulation development of protein drugs (liquid and lyophilized) Tech transfer for clinical manufacturing Stability and comparability studies Representing pharmaceutical development in cross-functional project teams Writing and executing protocols, summarizing of results in reports

  • Staff scientist at Formatech Inc.
    May 2006 - May 2010 · 4 yrs 1 mo

    Liquid and lyophilized formulation development of proteins, peptides and small molecule pharmaceuticals Project management and communication of results to clients with written reports and oral presentations Supervision of research associates

  • Research Associate at Dana-Farber Cancer Institute
    Aug 2000 - Apr 2006 · 5 yrs 9 mos

    Expression, crystallization and structure solution of a human T cell receptor/MHC II-peptide complex related to autoimmunity. Hahn, M., Nicholson, M.J., Pyrdol, J., and Wucherpfennig, K.W., (2005) Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol., 6, 490-496.

  • Staff scientist at Humboldt University Berlin
    Feb 1998 - Jul 2000 · 2 yrs 6 mos

    Structure solution of Fab-fragments in complex with synthetic peptides derived from combinatorial libraries Maintenance of x-ray equipment Training of students in protein crystallography Hahn, M., Winkler, D., Welfle, H., Welfle, K., Misselwitz, R., Wessner, H., Zahn, G., Scholz, C., Seiffert, M., Schneider-Mergener, J., and Höhne, W., (2001) Crossreactive binding of a cyclic peptide to an anti-TGF alpha antibody Fab-fragment. J. Mol. Biol. 314, 293-309.